Drug name: Xarelto
Companies: Johnson & Johnson and Bayer
Use: Anticoagulant
Amount spent on doctor payments: $6.93 million

Bayer and Johnson & Johnson's ($JNJ) Xarelto, second to join the next-gen anticoagulant fight, quickly began to grab market share from trailblazer Pradaxa after it hit the market. Among the two drugs and competitor Eliquis, companies have spent $20 million on speaking programs to educate doctors who may be wary of the warfarin replacements about their risks and benefits. The new-generation treatments don't require warfarin's constant dosage-monitoring or dietary restrictions but lack quick, FDA-approved antidotes. As a result, some doctors have been wary to prescribe them. Since its launch, Xarelto has won new indications, allowing J&J to expand its patient base through further doctor education. Thanks to the marketing push, Xarelto sales grew 76% from $864 million in 2013 to $1.5 billion in 2014. Johnson & Johnson and Bayer spent $6.93 million in 2014 on Xarelto doctor payments. -- Eric Sagonowsky (email)

For more:
How much for docs speaking on Eliquis, Xarelto and Pradaxa? $20M and counting
Bayer, J&J beef up Xarelto research to keep market-share gains coming


Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

As part of a multi-year asset offload, AstraZeneca has divested most of its global rights to constipation med Movantik to RedHill Biopharma.

Tazverik could beat consensus estimates thanks to current launch signs and an early FDA decision date for a label expansion, one analyst says.